Articles related to PATIENT SAFETY

Lithium continues to be recognized as the most reliable mood stabilizer for bipolar disorder patients with a history of mania, necessitating precise management of dosages to prevent significant side effects.

In the wake of allegations against Dr. Oluwafemi Esho, the medical community reflects on the critical importance of ethical conduct in maintaining patient trust and professional credibility.

In the recent phase 3 trial, recombinant ADAMTS13 demonstrated a profound capability to maintain ADAMTS13 activity at approximately 100% of normal levels, highlighting its potential to substantially reduce thrombotic complications in patients with congenital TTP.

Recent findings reveal chlormequat, a pesticide linked to reproductive toxicity, in 80% of urine samples across diverse US populations, reflecting its widespread presence in the food supply.

In the recent KEYNOTE-564 trial, adjuvant pembrolizumab therapy was shown to increase the 48-month overall survival rate to 91.2% compared to 86.0% with placebo among post-surgical patients with renal-cell carcinoma at increased risk of recurrence.

Philips Respironics has established a consent decree with US regulators to ensure the safety and compliance of their sleep and respiratory care devices, focusing on stringent remediation and continued patient support amidst ongoing sales restrictions.